Platelet Reactivity and Cardiovascular Mortality Risk in the LURIC Study.
Martin BergerAlexander DresselMarcus E KleberWinfried MärzPeter HellsternNikolaus MarxKatharina SchüttPublished in: Journal of clinical medicine (2023)
Cardiovascular mortality risk in patients with High- and Low platelet reactivity is equivalent to the presence of coronary artery disease. Targeted glucose control, improved kidney function and lower inflammation are associated with reduced mortality risk, however independent of platelet reactivity. In contrast, only in patients with High-platelet reactivity was Aspirin treatment associated with lower mortality.